Profile data is unavailable for this security.
About the company
Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. It also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. It also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.
- Revenue in AUD (TTM)677.54k
- Net income in AUD-13.87m
- Incorporated1984
- Employees1.00
- LocationBotanix Pharmaceuticals LtdSuite 3, 41-47 Colin Street, West PerthPERTH 6005AustraliaAUS
- Phone+61 86285-0083
- Fax+61 86210-1153
- Websitehttps://botanixpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals Inc | 301.75m | -398.47m | 546.36m | 384.00 | -- | 1.81 | -- | 1.81 | -3.82 | -3.82 | 2.87 | 2.86 | 0.5479 | 2.56 | 12.64 | 511,679.70 | -72.35 | -- | -84.00 | -- | 78.88 | -- | -132.05 | -- | 4.55 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| SCI Pharmtech Inc | 66.67m | 22.84m | 552.46m | 241.00 | 24.55 | 2.16 | 16.70 | 8.29 | 3.99 | 3.99 | 13.98 | 45.36 | 0.2211 | 1.82 | 4.61 | -- | 7.58 | 6.90 | 8.56 | 8.26 | 27.11 | 38.18 | 34.26 | 19.85 | 1.68 | 9.22 | 0.1692 | 42.38 | 33.83 | -9.10 | -4.55 | -8.00 | 44.67 | -16.35 |
| Probi AB | 87.53m | 1.51m | 555.29m | 157.00 | 367.45 | 2.92 | 35.68 | 6.34 | 0.9552 | 0.9552 | 55.33 | 120.07 | 0.4049 | 3.24 | 7.14 | 3,939,931.00 | 0.6991 | 4.64 | 0.7409 | 4.98 | 33.18 | 42.04 | 1.73 | 9.83 | 4.83 | -- | 0.0561 | 21.42 | 1.52 | 0.7684 | -58.60 | -26.09 | 31.01 | -- |
| Zhejiang Cheng Yi Pharmaceutical Co Ltd | 155.47m | 35.23m | 569.50m | 738.00 | 16.17 | 2.16 | -- | 3.66 | 0.5072 | 0.5072 | 2.24 | 3.80 | 0.4013 | 2.01 | 17.68 | 992,793.70 | 9.07 | 12.01 | 11.17 | 14.75 | 66.13 | 69.79 | 22.60 | 22.84 | 1.01 | -- | 0.1998 | 36.44 | 2.54 | 4.24 | 0.8129 | 10.94 | -23.56 | 12.84 |
| Botanix Pharmaceuticals Ltd | 677.54k | -13.87m | 572.50m | 1.00 | -- | 5.24 | -- | 844.97 | -0.0092 | -0.0092 | 0.0005 | 0.0601 | 0.0099 | -- | 1.59 | -- | -20.20 | -38.81 | -21.07 | -43.07 | -- | -- | -2,047.07 | -4,857.59 | 21.89 | -- | 0.00 | -- | 301.17 | 28.31 | -51.52 | -- | 323.01 | -- |
| Knight Therapeutics Inc | 383.17m | -33.77m | 587.17m | 725.00 | -- | 0.6915 | 26.89 | 1.53 | -0.2979 | -0.2979 | 3.42 | 7.66 | 0.3533 | 1.59 | 4.02 | 480,878.60 | -3.11 | 0.3477 | -3.53 | 0.4156 | 48.26 | 46.28 | -8.81 | 1.69 | 2.39 | 0.2385 | 0.07 | 0.00 | 11.80 | 92.24 | 43.68 | -- | 20.79 | -- |
| Frontier Biotechnologies Inc | 28.36m | -59.40m | 597.71m | 395.00 | -- | 2.45 | -- | 21.07 | -0.7474 | -0.7474 | 0.3569 | 3.07 | 0.0636 | 1.61 | 2.72 | 338,416.90 | -13.31 | -14.05 | -16.40 | -15.78 | 33.62 | 2.35 | -209.43 | -450.08 | 2.02 | -- | 0.2808 | -- | 34.82 | 126.63 | 7.79 | -- | 28.13 | -- |
| Enseval Putera Megatrading Tbk PT | 2.95bn | 70.95m | 624.29m | 5.13k | 8.81 | 0.8764 | 7.10 | 0.2118 | 271.32 | 271.32 | 11,263.57 | 2,727.06 | 2.77 | 7.15 | 7.07 | 5,975,601,000.00 | 6.64 | 7.63 | 9.97 | 10.80 | 9.84 | 10.71 | 2.40 | 2.86 | 1.53 | -- | 0.0312 | 64.35 | 1.71 | 6.71 | -18.76 | 1.06 | 8.20 | 13.02 |
| Holder | Shares | % Held |
|---|---|---|
| Antares Capital Partners Ltd.as of 31 Aug 2024 | 24.09m | 1.33% |
| Wilson Asset Management (International) Pty Ltd.as of 30 Jun 2024 | 12.17m | 0.67% |
| Netwealth Investments Ltd.as of 10 Sep 2024 | 8.28m | 0.46% |
| Allianz Global Investors Singapore Ltd.as of 31 Jul 2024 | 6.64m | 0.37% |
| Flinders Investment Partners Pty Ltd.as of 31 Aug 2024 | 4.37m | 0.24% |
| Fideuram Asset Management (Ireland) DACas of 31 Oct 2024 | 1.31m | 0.07% |
| AXA Investment Managers UK Ltd.as of 30 Sep 2024 | 977.21k | 0.05% |
| DFA Australia Ltd.as of 30 Sep 2024 | 782.46k | 0.04% |
| SSgA Funds Management, Inc.as of 07 Nov 2024 | 568.29k | 0.03% |
| Allianz Global Investors UK Ltd.as of 31 Jul 2024 | 516.59k | 0.03% |
